{"product_id":"algs-ansoff-analysis","title":"(ALGS) Aligos Therapeutics, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplore the Complete Growth Strategy Behind the Preview\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Aligos Therapeutics, Inc. Ansoff Matrix Analysis maps the company’s growth options across market penetration, market development, product development, and diversification and is meant to inform research, strategy, investing, or planning. This page already contains a real preview\/sample of the analysis so you can judge style and substance before buying—purchase the full version to receive the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2 HBV candidates in Phase I\/Ib\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAligos Therapeutics, Inc. has 2 HBV candidates in early clinical testing: ALG-010133 is in Phase Ib for chronic hepatitis B, and ALG-000184 is in Phase I. Running 2 programs in the same liver-disease niche deepens focus on one high-unmet-need market, where about 254 million people live with chronic hepatitis B worldwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e1 antisense HBsAg blocker\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALG-020572 is an antisense HBsAg blocker designed to stop HBsAg translation and secretion, keeping Aligos Therapeutics, Inc. in chronic hepatitis B while adding a distinct mechanism. Chronic HBV still affects about 254 million people worldwide, so the target market is large.\u003c\/p\u003e\n\u003cp\u003eThis supports market penetration, not expansion: Aligos can deepen HBV share with a second asset aimed at the same disease biology. It can strengthen its HBV story without moving outside its core focus.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e3 HBV siRNA assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAligos Therapeutics, Inc. is deepening penetration in chronic hepatitis B with 3 HBV siRNA assets: ALG-125755, ALG-125097, and ALG-125819. Each has shown potent HBsAg suppression in HBV-infected cells, giving the company multiple RNA shots in a market that still affects about 254 million people worldwide. That breadth can improve deal value and trial visibility inside the same HBV space.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003e1 NASH THR-ß agonist\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eALG-055009, Aligos Therapeutics, Inc.'s small-molecule THR-ß agonist, is in Phase 1a\/1b and extends the pipeline beyond HBV into MASH\/NASH. That keeps Aligos in hepatology, where the market is large and still underpenetrated, and supports cross-disease development.\u003c\/p\u003e\n\u003cp\u003eMaintaining HBV and NASH programs widens the same specialist base, so sales, data, and trial ops can be reused. In 2025, the key value is not near-term revenue but keeping one liver-focused franchise alive across two high-need indications.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase 1a\/1b asset\u003c\/li\u003e\n\u003cli\u003eExpands beyond HBV\u003c\/li\u003e\n\u003cli\u003eTargets hepatology overlap\u003c\/li\u003e\n\u003cli\u003eSupports market concentration\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003e4 strategic alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAligos Therapeutics, Inc. uses 4 alliances with Luxna Biotech, Emory University, Katholieke Universiteit Leuven, and Merck to strengthen its existing viral and liver disease programs. These ties help keep work moving in hepatitis B, delta, and related liver science, where outside expertise can speed data generation and reduce strain on internal resources. In 2024, Aligos reported $26.9 million in revenue, showing these partnerships matter for pipeline support.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e4 alliances support core viral and liver programs\u003c\/li\u003e\n\u003cli\u003eExternal partners add research speed and depth\u003c\/li\u003e\n\u003cli\u003ePartnerships help sustain current focus areas\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAligos Stacks 3 HBV Assets on a 254M-Patient Opportunity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAligos Therapeutics, Inc. is using market penetration in chronic hepatitis B by stacking multiple HBV assets, including ALG-010133, ALG-000184, and ALG-020572, inside one high-need market of about 254 million people worldwide. That keeps development, data, and partner value centered on the same liver franchise. In 2024, Aligos reported $26.9 million in revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHBV patients\u003c\/td\u003e\n\u003ctd\u003e254 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$26.9 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHBV assets\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOutlines Aligos Therapeutics, Inc.’s growth options across existing and new products and markets\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise Ansoff Matrix for Aligos Therapeutics, Inc., helping teams quickly align growth options and reduce strategic planning friction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, vetted bibliography linking each Ansoff growth path for Aligos Therapeutics to primary sources for faster, defensible strategy and due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLuxna HBV collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAligos Therapeutics, Inc.'s Luxna Biotech licensing deal supports HBV genome-targeting oligonucleotides, adding an external partner channel to extend its HBV pipeline. The move fits market development by widening reach into new R\u0026amp;D networks without changing the core HBV science. This matters in a market with about 254 million people living with chronic HBV and 1.1 million new infections a year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmory HBV technology transfer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAligos Therapeutics, Inc.'s Emory University transfer for HBV capsid assembly modulator tech expands market development beyond its South San Francisco base. The channel matters because chronic hepatitis B still affects about 254 million people worldwide, so academic access can speed validation and partner reach. It also widens Aligos’ institutional network for HBV pipeline growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKU Leuven Europe channel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAligos Therapeutics, Inc. uses its agreement with Katholieke Universiteit Leuven on coronavirus protease inhibitors to build a European research channel, extending its development footprint beyond the U.S. The tie-up gives Aligos access to a top EU biotech hub and can speed early-stage work with lower capital than building a full local lab. In market-development terms, it is geographic expansion through partnership, not direct market entry.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMerck pharma channel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAligos Therapeutics, Inc. uses the Merck pharma channel as market development: the NASH oligonucleotide deal plugs it into Merck’s large drug-development network and can widen access to liver-disease expertise, trial sites, and regulatory support. That matters in NASH, where late-stage studies are costly and slow. Merck also brings big-pharma reach, with annual revenue above $60 billion.\u003c\/p\u003e\n\u003cp\u003eFor Aligos Therapeutics, Inc., this is a low-capital way to extend one liver program into a broader partner ecosystem. It can speed validation, cut execution risk, and make future partnering more credible.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpands access to Merck's development resources\u003c\/li\u003e\n\u003cli\u003eStrengthens NASH market reach\u003c\/li\u003e\n\u003cli\u003eReduces solo R\u0026amp;D burden\u003c\/li\u003e\n\u003cli\u003eImproves partner credibility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMulti-site clinical execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAligos Therapeutics, Inc. is using multi-site clinical execution to push ALG-010133, ALG-000184, and ALG-055009 beyond a single-center footprint. That matters because early-stage programs need broader investigator and patient networks to speed enrollment and improve data quality. It is a practical Market Development move: take the same assets into more clinical markets without changing the core pipeline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroader site reach can lift enrollment speed.\u003c\/li\u003e\n\u003cli\u003eMore investigators can expand patient access.\u003c\/li\u003e\n\u003cli\u003eMulti-site runs support cleaner, scalable data.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAligos Expands HBV Reach Through Strategic Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAligos Therapeutics, Inc. uses partner-led expansion to reach more HBV and liver-disease networks without changing its core science. Luxna, Emory, Leuven, Merck, and multi-site trials widen access to research hubs, trial sites, and development know-how in a field with about 254 million chronic HBV cases and 1.1 million new infections a year.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMarket development lever\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHBV addressable burden\u003c\/td\u003e\n\u003ctd\u003e254 million chronic cases; 1.1 million new infections\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner reach\u003c\/td\u003e\n\u003ctd\u003eLuxna, Emory, Leuven, Merck\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eAligos Therapeutics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just a professional, structured review of Aligos Therapeutics' market penetration, product development, market development, and diversification options to guide strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eALG-010133 Phase Ib\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALG-010133 is Aligos Therapeutics, Inc.'s Phase Ib s-antigen transport-inhibiting oligonucleotide polymer for chronic hepatitis B, so it fits Ansoff's product development: a new product for an existing market. HBV still affects about 254 million people worldwide, which keeps the addressable market large. Phase Ib means Aligos is still testing safety and early efficacy before any broader commercial push.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eALG-000184 Phase I\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALG-000184 is Aligos Therapeutics, Inc.'s Phase I capsid assembly modulator for chronic hepatitis B, a market with about 254 million people living with the disease worldwide. In Ansoff terms, it is product development: a new HBV therapy aimed at the company’s existing liver-disease focus. If Phase I data support safety and antiviral activity, it could broaden Aligos Therapeutics, Inc.'s pipeline beyond its current programs and target a large unmet need.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eALG-020572 antisense program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALG-020572 is an antisense oligonucleotide that blocks HBsAg translation and secretion, so it adds a new RNA-based tool to Aligos Therapeutics, Inc.'s HBV set. In Ansoff terms, that is product development: same hepatitis B market, new mechanism. With chronic hepatitis B still affecting about 254 million people worldwide, the asset can deepen pipeline breadth without leaving the core market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003e3 HBV siRNA candidates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAligos Therapeutics, Inc. has 3 HBV siRNA candidates—ALG-125755, ALG-125097, and ALG-125819—that showed potent inhibition of HBsAg release from HBV-infected cells, adding a separate modality class to its HBV pipeline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 siRNA assets\u003c\/li\u003e\n\u003cli\u003eHBsAg release blocked\u003c\/li\u003e\n\u003cli\u003ePipeline now spans multiple modalities\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eALG-055009 Phase 1a\/1b\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eALG-055009 is a small-molecule THR-β agonist in Phase 1a\/1b for NASH, giving Aligos Therapeutics, Inc. a second liver-disease shot beyond HBV. In Ansoff terms, this is product development: the company is using its existing biotech platform to build a new therapy for a related disease area. It also broadens pipeline risk away from HBV alone.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003ePhase 1a\/1b\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eTHR-β agonist\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eNew liver-disease asset\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eDiversifies beyond HBV\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAligos Expands HBV Pipeline With New Liver Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAligos Therapeutics, Inc. uses product development to add new HBV assets to its core market. ALG-010133, ALG-000184, ALG-020572, and the 3 siRNA candidates extend its hepatitis B pipeline, while ALG-055009 adds a non-HBV liver program. Chronic hepatitis B still affects about 254 million people worldwide.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eFit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eALG-010133\u003c\/td\u003e\n\u003ctd\u003ePhase Ib\u003c\/td\u003e\n\u003ctd\u003eNew HBV product\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eALG-055009\u003c\/td\u003e\n\u003ctd\u003ePhase 1a\/1b\u003c\/td\u003e\n\u003ctd\u003eNew liver area\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCoronavirus protease inhibitors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAligos Therapeutics, Inc. is diversifying by licensing coronavirus protease inhibitors from Katholieke Universiteit Leuven, which moves it beyond its HBV and NASH core. This is a clear product and market extension into antivirals, adding a new viral target with a different commercial path. For a company still centered on a few programs, this reduces concentration risk and broadens its pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHBV genome-targeting oligonucleotides\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAligos Therapeutics, Inc. uses the Luxna Biotech deal to add HBV genome-targeting oligonucleotides, a distinct external platform, to its HBV portfolio. That fits diversification in the Ansoff Matrix: it widens the product base through partner-led innovation instead of relying on one internal approach. The angle matters in HBV, where WHO still estimates about 254 million people live with chronic infection.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHBV capsid modulator technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAligos Therapeutics, Inc.'s Emory University partnership on HBV capsid assembly modulators adds a second antiviral mechanism, so it is not tied to one drug path. In Ansoff terms, that is diversification across modalities: one research base, multiple shots on goal. For HBV, where over 250 million people live with chronic infection worldwide, spreading risk across mechanisms can improve pipeline resilience.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNASH oligonucleotides with Merck\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAligos Therapeutics, Inc.’s Merck collaboration adds NASH-oriented oligonucleotides, so the company is not relying only on its internal small-molecule liver program. That broadens its diversification in a distinct modality, with a major pharma partner backing an outside platform. It also lowers single-asset concentration by spreading risk across product formats and development paths.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMerck adds external NASH depth.\u003c\/li\u003e\n\u003cli\u003eOligonucleotides differ from small molecules.\u003c\/li\u003e\n\u003cli\u003ePartnership broadens pipeline mix.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003e5-modality pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAligos Therapeutics’ 5-modality pipeline spans an oligonucleotide polymer, a capsid modulator, an antisense oligonucleotide, siRNA candidates, and a THR-ß agonist. That spread cuts reliance on one asset or one drug class, and it diversifies risk across viral and liver disease programs. In Ansoff terms, it supports product diversification with multiple shots on goal.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFive modalities, one portfolio\u003c\/li\u003e\n\u003cli\u003eLower single-asset risk\u003c\/li\u003e\n\u003cli\u003eBroader viral and liver disease reach\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAligos Expands Beyond HBV with a Diversified 5-Modality Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAligos Therapeutics, Inc. uses diversification in Ansoff terms by adding outside antiviral and liver-disease platforms beyond its core HBV and NASH work. Its 5-modality pipeline and HBV programs spread risk across drugs, targets, and partners, while chronic HBV still affects about 254 million people worldwide.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eModalities\u003c\/td\u003e\n\u003ctd\u003e5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHBV burden\u003c\/td\u003e\n\u003ctd\u003e254 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategy\u003c\/td\u003e\n\u003ctd\u003eDiversification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57233955782921,"sku":"algs-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/algs-ansoff-matrix.webp?v=1785710231","url":"https:\/\/dcfanalyst.com\/products\/algs-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}